Treatment of metastatic colorectal cancer: focus on panitumumab

被引：18
|
作者：
Tay, Rebecca Y. [1 ]
Wong, Rachel [1 ,2 ,3 ]
Hawkes, Eliza A. [1 ,3 ,4 ]
机构：
[1] Eastern Hlth, Dept Med Oncol, Box Hill, Vic, Australia
[2] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia
[3] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[4] Austin Hosp, Olivia Newton John Canc & Wellness Ctr, Dept Oncol, Level 4, Heidelberg, Vic 3084, Australia
来源：
CANCER MANAGEMENT AND RESEARCH | 2015年 / 7卷
关键词：
panitumumab; metastatic colorectal cancer; KRAS; RAS; EGFR; monoclonal antibody; WILD-TYPE KRAS; PHASE-III TRIAL; OPEN-LABEL; 1ST-LINE TREATMENT; RANDOMIZED-TRIAL; PLUS IRINOTECAN; CLINICAL-TRIAL; RAS MUTATIONS; CETUXIMAB; FLUOROURACIL;
D O I：
10.2147/CMAR.S71821
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Targeted agents are an important therapeutic option in the treatment of metastatic colorectal cancer (mCRC). Panitumumab is a recombinant, fully humanized, immunoglobulin G2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) with efficacy in mCRC as monotherapy and in combination with chemotherapy. Kirsten rat sarcoma (KRAS) mutation status has emerged as an important biomarker to predict response to anti-EGFR therapy. Optimal timing for panitumumab use in the mCRC treatment algorithm has not been established. This review discusses the mechanism of action, predictive biomarkers, and role of panitumumab in the treatment of mCRC.
引用
收藏
页码：189 / 198
页数：10
相关论文
共 50 条
  • [1] Panitumumab - In the treatment of metastatic colorectal cancer
    Hoy, Sheridan M.
    Wagstaff, Antona J.
    [J]. DRUGS, 2006, 66 (15) : 2005 - 2014
  • [2] Metastatic colorectal cancer: treatment with panitumumab
    Silvinato, Antonio
    Pedreira, Isabela da Silveira
    Bueno dos Reis, Joao Conrado
    Zetula Marcondes, Joao Guilherme
    Bernardo, Wanderley M.
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2018, 64 (07): : 568 - 574
  • [3] Panitumumab for the treatment of metastatic colorectal cancer
    Pinguet, Frederic
    [J]. EJHP PRACTICE, 2009, 15 (06): : 66 - 69
  • [4] Panitumumab for the treatment of metastatic colorectal cancer: a review
    Del Prete, M.
    Giampieri, R.
    Faloppi, L.
    Bianconi, M.
    Bittoni, A.
    Andrikou, K.
    Cascinu, S.
    [J]. IMMUNOTHERAPY, 2015, 7 (07) : 721 - 738
  • [5] Panitumumab in the treatment of metastatic colorectal cancer - Profile report
    Hoy, Sheridan M.
    Wagstaff, Antona J.
    [J]. BIODRUGS, 2007, 21 (02) : 135 - 137
  • [6] Panitumumab in metastatic colorectal cancer
    Hocking, Christopher M.
    Townsend, Amanda R.
    Price, Timothy J.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (07) : 781 - 793
  • [7] Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
    Freeman, Daniel J.
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 633 - 645
  • [8] Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
    Lopez-Gomez, Miriam
    Merino, Maria
    Casado, Enrique
    [J]. CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [9] Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer
    Berardi, Rossana
    Onofri, Azzurra
    Pistelli, Mirco
    Maccaroni, Elena
    Scartozzi, Mario
    Pierantoni, Chiara
    Cascinu, Stefano
    [J]. CORE EVIDENCE, 2010, 5 : 61 - 76
  • [10] Spotlight on Panitumumab in Metastatic Colorectal Cancer
    Keating, Gillian M.
    [J]. BIODRUGS, 2010, 24 (04) : 275 - 278
12345